Antipsychotic Medications and Drug‐Induced Movement Disorders Other Than Parkinsonism: A Population‐Based Cohort Study in Older Adults

Objectives: To study the relationship between initiating therapy with an antipsychotic medication and a subsequent new diagnosis of a drug‐induced movement disorder other than parkinsonism in older adults with dementia.

[1]  R. Trosch.  Neuroleptic‐Induced Movement Disorders: Deconstructing Extrapyramidal Symptoms , 2004, Journal of the American Geriatrics Society.

[2]  T. Macewan,et al.  CSM warning on atypical psychotics and stroke may be detrimental for dementia , 2004, BMJ : British Medical Journal.

[3]  Geoff M. Anderson,et al.  Neuroleptic Drug Therapy in Older Adults Newly Admitted to Nursing Homes: Incidence, Dose, and Specialist Contact , 2004, Journal of the American Geriatrics Society.

[4]  C. Correll,et al.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. , 2004, The American journal of psychiatry.

[5]  R. Goldberg.  Tardive dyskinesia in elderly patients: an update. , 2003, Journal of the American Medical Directors Association.

[6]  R. Chaplin.  Risperidone, tardive dyskinesia, and the elderly. , 2001, The American journal of psychiatry.

[7]  D. Jeste,et al.  Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. , 2000, The American journal of psychiatry.

[8]  Philip D. Harvey,et al.  A long‐term, multicenter, open‐label study of risperidone in elderly patients with psychosis , 2000, International journal of geriatric psychiatry.

[9]  D. Jeste,et al.  Lower Incidence of Tardive Dyskinesia with Risperidone Compared with Haloperidol in Older Patients , 1999, Journal of the American Geriatrics Society.

[10]  R. Tandon,et al.  The efficacy, safety, and tolerability of antipsychotics in the elderly. , 1999, The Journal of clinical psychiatry.

[11]  J. Lieberman,et al.  Prospective study of tardive dyskinesia in the elderly: rates and risk factors. , 1998, The American journal of psychiatry.

[12]  T. Einarson,et al.  Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. , 1998, The Journal of clinical psychiatry.

[13]  R. Rosenheck,et al.  A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.

[14]  R. Tamura,et al.  Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. , 1997 .

[15]  D. Jeste,et al.  Neuroleptic-Induced Movement Disorders: Treatment of tardive dyskinesia , 1996 .

[16]  Jane S. Paulsen,et al.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. , 1995, Archives of General Psychiatry.

[17]  L. Sata.  A TASK FORCE REPORT OF THE AMERICAN PSYCHIATRIC ASSOCIATION , 1994 .

[18]  J. Avorn,et al.  Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. , 1994, Archives of internal medicine.

[19]  J. Lieberman,et al.  Prospective study of tardive dyskinesia incidence in the elderly. , 1991, JAMA.

[20]  L. Schneider,et al.  A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia , 1990, Journal of the American Geriatrics Society.

[21]  G. Chouinard,et al.  A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. , 1988, Journal of clinical psychopharmacology.

[22]  R. Baldessarini,et al.  Changes in prevalence, severity, and recovery in tardive dyskinesia with age. , 1980, Archives of general psychiatry.

[23]  G. Crane.  Persistent Dyskinesia , 1973, British Journal of Psychiatry.